Meiragtx Holdings plc, of New York, has filed to raise up to $86 million in an IPO. Once the offering has priced the company expects that its shares will trade on the Nasdaq under the symbol MGTX. Using gene therapies, it will develop a product pipeline focused on inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases.